Finance

Lists
CTNM:NASDAQ
Contineum Therapeutics Inc
11,50 US$
0,00%
(0,00) 1D
11,60 US$
+0,87% (+0,10)
Pre-market
Closed: 29 სექ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Mkt. cap
432,64 მლნ.
Avg. vol.
528,40 ათ.
Volume
3,38 ათ.
52-wk high
17,78 US$
52-wk low
8,60 US$
EPS
-1,74 US$
Shares outstanding
32,96 მლნ.
No. of employees
51
Mkt. cap
432,64 მლნ.
Avg. vol.
528,40 ათ.
Volume
3,38 ათ.
52-wk high
17,78 US$
52-wk low
8,60 US$
EPS
-1,74 US$
Shares outstanding
32,96 მლნ.
No. of employees
51
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorPharmaceutical industry
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current 11,50 US$
28,00 US$ (+143,48%)
Average
22,00 US$ (+91,30%)
Lowest
17,00 US$ (+47,83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Maintained
23,00 US$
+100%
09/29/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
17,00 US$
+47,8%
09/28/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
24,00 US$
+108,7%
09/27/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/23/2026
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 US$
+82,6%
09/21/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
22,00 US$
+91,3%
09/16/2026
Charles Moore
Robert W. Baird
Buy
Maintained
19,00 US$
+65,2%
09/15/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
28,00 US$
+143,5%
09/15/2026
Last report
30 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,40 US$ / -0,45 US$
+10,83%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,50 მლნ.
12,00 მლნ.
11,14 მლნ.
11,97 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,43 მლნ.
5,12 მლნ.
5,76 მლნ.
5,45 მლნ.
Operating expense
14,93 მლნ.
17,12 მლნ.
16,90 მლნ.
17,43 მლნ.
Total operating expenses
14,93 მლნ.
17,12 მლნ.
16,90 მლნ.
17,43 მლნ.
Operating income
-14,93 მლნ.
-17,12 მლნ.
-16,90 მლნ.
-17,43 მლნ.
Other non operating income
183,00 ათ.
-51,00 ათ.
-57,00 ათ.
-68,00 ათ.
EBT including unusual items
-12,79 მლნ.
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
EBT excluding unusual items
-12,79 მლნ.
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,79 მლნ.
-15,16 მლნ.
-14,46 მლნ.
-15,15 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,45
-0,49
-0,39
-0,40
Interest and investment income
1,96 მლნ.
2,01 მლნ.
2,50 მლნ.
2,34 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,96 მლნ.
2,01 მლნ.
2,50 მლნ.
2,34 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-14,85 მლნ.
-17,03 მლნ.
-16,82 მლნ.
-17,29 მლნ.
Gain or loss from assets sale
-
-
2,00 ათ.
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები